Progenity: Funding, Investors & Team (Oct 2026)
Progenity, Inc. is a biotechnology company with an established track record of success in developing and commercializing molecular testing products, as well as innovating in the field of precision medicine. Progenity provides in vitro molecular tests designed to improve lives by providing actionable information that helps guide patients and physicians in making medical decisions during key life stages. The company applies a multi-omics approach, combining genomics, epigenomics, proteomics, and metabolomics to its molecular testing products and to the development of a suite of investigational ingestible devices designed to provide precise diagnostic sampling and drug delivery solutions. Progenity’s vision is to transform healthcare to become more precise and personal by improving diagnoses of disease and improving patient outcomes through localized treatment with targeted therapies.
Progenity has raised $60.0M across 2 funding rounds on record, the most recent a Post-IPO Equity of $20.0M announced in Oct 2021.
That round is above the $8.1M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Progenity Company Profile and Key Stats
Latest funding round on record: Oct 2021.
Progenity Funding Rounds
Progenity raised $40.0M in an undisclosed round announced in Jun 2021.
4 months later, a Post-IPO Equity of $20.0M was announced in Oct 2021.
Progenity Founders and Leadership Team
Contact details for the Progenity team: 1 of 1 has an email address on file.
Start 14-day free trial →Progenity Funding Compared to Other Biotechnology Startups
Progenity's latest round of $20.0M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Progenity in Biotechnology and Carlsbad
Companies Similar to Progenity
Kallyope, we believe that the gut is the gateway to our internal world. Containing millions of neurons, the…
Astrocyte Pharmaceuticals is a drug development company that helps in the recovery and well-being of brain…
Tiny Health offers a gut health test specifically designed for mothers and babies aged 0 to 3 years.…
Junevity is dedicated to using cutting-edge transcription factor medicines to combat age-related diseases.…
Arkea Bio creates technology aimed at reducing greenhouse gas (GHG) emissions in the agricultural sector.
Serán is a contract development and manufacturing organization providing a comprehensive suite of…
Precision’s goal is to provide breakthrough treatments for the one billion patients worldwide suffering from…
Enveda is a biotechnology company that utilizes AI-powered tools to explore and characterize molecules from…
Avery Therapeutics, Inc. is a company dedicated to developing tissue engineered therapeutics to treat…
Circle Pharma is a biotechnology company in the initial stages of development that uses unique computational…
Evvy is for people with vaginas who want to be empowered with information about their microbiome. Their…
Progenity Funding FAQs
What does Progenity do?
Progenity, Inc. is a biotechnology company with an established track record of success in developing and commercializing molecular testing products, as well as innovating in the field of precision medicine. Progenity provides in vitro molecular tests designed to improve lives by providing actionable information that helps guide patients and physicians in making medical decisions during key life stages. The company applies a multi-omics approach, combining genomics, epigenomics, proteomics, and metabolomics to its molecular testing products and to the development of a suite of investigational ingestible devices designed to provide precise diagnostic sampling and drug delivery solutions. Progenity’s vision is to transform healthcare to become more precise and personal by improving diagnoses of disease and improving patient outcomes through localized treatment with targeted therapies.
How much funding has Progenity raised?
Progenity has raised $60.0M across 2 rounds on record. The most recent is a Post-IPO Equity of $20.0M announced in Oct 2021.
When did Progenity last raise funding?
Progenity's most recent funding round on record is a Post-IPO Equity of $20.0M, announced in Oct 2021.
Who is the CEO of Progenity?
Harry Stylli is listed as CEO at Progenity.
Where is Progenity headquartered?
Progenity is based in Carlsbad, California, United States.
How many employees does Progenity have?
Progenity is in the 251-500 employee band.
How does Progenity's funding compare to other Biotechnology startups?
Progenity's latest round of $20.0M is above the $8.1M median round size for Biotechnology companies on FundedIQ across 4,185 tracked companies over the last two years.
About FundedIQ's Progenity Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Progenity is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Startup funding intelligence on every funded startup: the round, the investors and the founders, as a file in your inbox or searchable in the app.
Radar from $49/mo · Pro from $149/mo. Card required, nothing charged until day 15, and we email you 3 days before that. Need something specific? Custom plans from $499/mo.